首页 > 最新文献

International Journal of Women''s Dermatology最新文献

英文 中文
Vulvar squamous cell carcinoma guidelines do not include tissue-sparing techniques as a treatment option. 外阴鳞状细胞癌指南不包括组织保留技术作为一种治疗选择。
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000078
Cesar A Virgen, Isabella I Sanchez, Ashley N Elsensohn, Christina N Kraus
{"title":"Vulvar squamous cell carcinoma guidelines do not include tissue-sparing techniques as a treatment option.","authors":"Cesar A Virgen, Isabella I Sanchez, Ashley N Elsensohn, Christina N Kraus","doi":"10.1097/JW9.0000000000000078","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000078","url":null,"abstract":"","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e078"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c4/6f/jw9-9-e078.PMC9995084.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Orange palpebral spots: a rare entity of unknown clinical significance. 橙色眼睑斑点:一种罕见的实体,临床意义未知。
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000072
Gloria Munayco Maldonado, Zelma Chiesa Fuxench
Orange palpebral spots (OPS) is a rarely described entity of unknown etiology first reported in 2008 by Assouly et al.1 OPS most commonly presents on females as flat, nonpalpable lesions on the superior eyelids. The coloration of OPS tends to vary between yellow-orange and light orange. Due to this, it has been previously suggested that the nomenclature be expanded to “yellow-orange palpebral spots.” Herein, we present the case of a 53-year-old woman with a 2-year history of asymptomatic, yellow-orange patches on the upper eyelids (Fig. 1). Medical history was unremarkable except for gastroesophageal reflux disease and depression treated with omeprazole and escitalopram, respectively. Our patient did not recall any triggers and denied the use of makeup, protective eyewear (ie, goggles), or contact lens solution. Skin examination was remarkable for the presence of well-defined, yellow-to-orange patches on the medial upper eyelids. Lipid panel was within normal limits. No other testing was performed. Given the patient’s clinical presentation, a diagnosis of OPS was favored. The differential diagnosis of OPS includes xanthoma or xanthelasma. OPS, unlike xanthelasma or xanthoma, do not have an elevated appearance with coloration that varies between yellow-orange to light orange.1,2 Skin biopsies of OPS have shown increased adipose tissue and pigment-laden macrophages in the superficial dermis without the characteristic lipid-laden macrophages of xanthelasma.1,2 In our case, because a diagnosis of OPS was favored at the outset and because of the sensitive location of these lesions, a biopsy was not performed. While xanthelasma tends to correlate with hyperlipidemia, patients with OPS present with normal lipid levels and lipid screens are often uncecessary.1 In our case, the patient’s primary care physician had ordered a lipid panel as routine lab work. Evolution of these 2 distinct conditions has not found them to be interlinked as patients that have been followed for xanthelasma have never shown clinical features of OPS and vice versa.1 The differential diagnoses of OPS also include use of fluorescein solutions in ophthalmology and necrobiotic xanthogranuloma. However, staining due to fluorescein solution typically affects the lower eyelids.1,3 Necrobiotic xanthogranuloma involves the periorbital area in addition to the eyelids and is often seen in patients with monoclonal gammopathy and clinically present with red-tobrown, violaceous, or yellowish papules and nodules.1,3 The etiology of OPS remains to be fully elucidated. Assouly et al.1 proposed a correlation between OPS and high levels of vitamin E, total carotenoids, or β-cryptoxanthin secondary to high citrus consumption.1,4 Our patient maintained a low-citrus diet due to her history of gastroesophageal reflux disease indicating that exposure to high levels of the previously mentioned compounds was unlikely. Belliveau et al.2 also described melanin incontinence in the histopathologic analysis of
{"title":"Orange palpebral spots: a rare entity of unknown clinical significance.","authors":"Gloria Munayco Maldonado, Zelma Chiesa Fuxench","doi":"10.1097/JW9.0000000000000072","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000072","url":null,"abstract":"Orange palpebral spots (OPS) is a rarely described entity of unknown etiology first reported in 2008 by Assouly et al.1 OPS most commonly presents on females as flat, nonpalpable lesions on the superior eyelids. The coloration of OPS tends to vary between yellow-orange and light orange. Due to this, it has been previously suggested that the nomenclature be expanded to “yellow-orange palpebral spots.” Herein, we present the case of a 53-year-old woman with a 2-year history of asymptomatic, yellow-orange patches on the upper eyelids (Fig. 1). Medical history was unremarkable except for gastroesophageal reflux disease and depression treated with omeprazole and escitalopram, respectively. Our patient did not recall any triggers and denied the use of makeup, protective eyewear (ie, goggles), or contact lens solution. Skin examination was remarkable for the presence of well-defined, yellow-to-orange patches on the medial upper eyelids. Lipid panel was within normal limits. No other testing was performed. Given the patient’s clinical presentation, a diagnosis of OPS was favored. The differential diagnosis of OPS includes xanthoma or xanthelasma. OPS, unlike xanthelasma or xanthoma, do not have an elevated appearance with coloration that varies between yellow-orange to light orange.1,2 Skin biopsies of OPS have shown increased adipose tissue and pigment-laden macrophages in the superficial dermis without the characteristic lipid-laden macrophages of xanthelasma.1,2 In our case, because a diagnosis of OPS was favored at the outset and because of the sensitive location of these lesions, a biopsy was not performed. While xanthelasma tends to correlate with hyperlipidemia, patients with OPS present with normal lipid levels and lipid screens are often uncecessary.1 In our case, the patient’s primary care physician had ordered a lipid panel as routine lab work. Evolution of these 2 distinct conditions has not found them to be interlinked as patients that have been followed for xanthelasma have never shown clinical features of OPS and vice versa.1 The differential diagnoses of OPS also include use of fluorescein solutions in ophthalmology and necrobiotic xanthogranuloma. However, staining due to fluorescein solution typically affects the lower eyelids.1,3 Necrobiotic xanthogranuloma involves the periorbital area in addition to the eyelids and is often seen in patients with monoclonal gammopathy and clinically present with red-tobrown, violaceous, or yellowish papules and nodules.1,3 The etiology of OPS remains to be fully elucidated. Assouly et al.1 proposed a correlation between OPS and high levels of vitamin E, total carotenoids, or β-cryptoxanthin secondary to high citrus consumption.1,4 Our patient maintained a low-citrus diet due to her history of gastroesophageal reflux disease indicating that exposure to high levels of the previously mentioned compounds was unlikely. Belliveau et al.2 also described melanin incontinence in the histopathologic analysis of","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e072"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/98/c7/jw9-9-e072.PMC9886507.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10650696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A retrospective study on the association of keloids with underlying health conditions in African-American Women. 非裔美国妇女瘢痕疙瘩与潜在健康状况关联的回顾性研究
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000074
Pooja Marella, Donald A Glass

Keloids are disfiguring benign scars that develop due to an exaggerated response to cutaneous wound healing, growing beyond the boundaries of the cutaneous insult into normal, previously uninvolved skin. The association of keloids with other underlying health conditions has been postulated, but not well characterized.

Objective: This study aims to identify whether there is any association of keloids with underlying health conditions in African-American women.

Methods: This study was done via the use of the National Inpatient Sample, a subset of the Healthcare Cost and Utilization Project. African-American women with keloids who had undergone cesarean sections were compared with a control group of African-American women with no history of keloids who had undergone cesarean sections.

Results: A total of 301 African-American inpatient encounters with patients with keloids were compared with 37,144 encounters in the control group. The keloid patients had an increased association with peritoneal adhesions compared with the control group.

Limitations: results are limited to one race and restricted age range; also, unable to differentiate keloids from hypetrophic scarring with ICD-10 codes.

Conclusion: These findings suggest that keloids and peritoneal adhesions may have similar inflammatory processes.

瘢痕疙瘩是一种毁容的良性疤痕,由于皮肤伤口愈合的过度反应而形成,生长超出皮肤损伤的边界,进入正常的、先前未受损伤的皮肤。瘢痕疙瘩与其他潜在健康状况的关联已被假设,但尚未很好地表征。目的:本研究旨在确定非裔美国女性瘢痕疙瘩是否与潜在健康状况有关。方法:本研究通过使用全国住院病人样本,医疗成本和利用项目的一个子集来完成。研究人员将有瘢痕疙瘩的非裔美国妇女剖宫产手术与没有瘢痕疙瘩病史的非裔美国妇女剖宫产手术进行比较。结果:共有301例非裔美国住院患者与瘢痕疙瘩患者的接触与对照组的37,144例接触进行了比较。与对照组相比,瘢痕疙瘩患者与腹膜粘连的相关性增加。局限性:结果仅限于一个种族和限定的年龄范围;此外,无法区分瘢痕疙瘩和瘢痕增生与ICD-10代码。结论:这些发现提示瘢痕疙瘩和腹膜粘连可能具有相似的炎症过程。
{"title":"A retrospective study on the association of keloids with underlying health conditions in African-American Women.","authors":"Pooja Marella,&nbsp;Donald A Glass","doi":"10.1097/JW9.0000000000000074","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000074","url":null,"abstract":"<p><p>Keloids are disfiguring benign scars that develop due to an exaggerated response to cutaneous wound healing, growing beyond the boundaries of the cutaneous insult into normal, previously uninvolved skin. The association of keloids with other underlying health conditions has been postulated, but not well characterized.</p><p><strong>Objective: </strong>This study aims to identify whether there is any association of keloids with underlying health conditions in African-American women.</p><p><strong>Methods: </strong>This study was done via the use of the National Inpatient Sample, a subset of the Healthcare Cost and Utilization Project. African-American women with keloids who had undergone cesarean sections were compared with a control group of African-American women with no history of keloids who had undergone cesarean sections.</p><p><strong>Results: </strong>A total of 301 African-American inpatient encounters with patients with keloids were compared with 37,144 encounters in the control group. The keloid patients had an increased association with peritoneal adhesions compared with the control group.</p><p><strong>Limitations: </strong>results are limited to one race and restricted age range; also, unable to differentiate keloids from hypetrophic scarring with ICD-10 codes.</p><p><strong>Conclusion: </strong>These findings suggest that keloids and peritoneal adhesions may have similar inflammatory processes.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e074"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e0/cc/jw9-9-e074.PMC9949828.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10794232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 vaccination among patients with cicatricial alopecia: patient concerns, experiences, and treatment modifications. 瘢痕性脱发患者的COVID-19疫苗接种:患者的担忧、经验和治疗修改
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000036
Kelly E Flanagan, James T Pathoulas, Maryanne M Senna, Chloe J Walker, Isabel Pupo Wiss, Maya Collins, Shaheir Ali, Rita Wanser, Jean Pickford, Wilma Bergfeld
{"title":"COVID-19 vaccination among patients with cicatricial alopecia: patient concerns, experiences, and treatment modifications.","authors":"Kelly E Flanagan,&nbsp;James T Pathoulas,&nbsp;Maryanne M Senna,&nbsp;Chloe J Walker,&nbsp;Isabel Pupo Wiss,&nbsp;Maya Collins,&nbsp;Shaheir Ali,&nbsp;Rita Wanser,&nbsp;Jean Pickford,&nbsp;Wilma Bergfeld","doi":"10.1097/JW9.0000000000000036","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000036","url":null,"abstract":"","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e036"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/19/jw9-9-e036.PMC9973349.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10824275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analyzing trends in treatment of acne vulgaris in pregnancy: a retrospective study. 妊娠期寻常痤疮治疗趋势分析:一项回顾性研究。
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000076
Swati P Garg, Saira Alvi, Roopal V Kundu
Acne vulgaris is an inflammatory disease of the skin common in pregnancy.1 Many first-line acne treatments are teratogenic, complicating management of this condition (Table 1).2 Although recommendations from the American Board of Family Medicine (ABFM) exist for treatment of acne in pregnancy,3 no studies have analyzed real-life data of acne management in pregnant patients. A retrospective study utilizing patient data from the Northwestern Medicine Enterprise Data Warehouse was approved by the Northwestern University Institutional Review Board (STU00037913). Data from over 40 clinic locations and 100 providers across the Chicago metropolitan area resulted in 4,050 analyzed patient encounters with a diagnosis of acne vulgaris. One hundred fifteen of these visits occurred in pregnancy-related encounters. Within our 115 patients, 57.4% (66) of patients were trying to get pregnant within the next year, 32.2% (37) were pregnant, and 10.4% (12) were breastfeeding (Table 2). Patients in this cohort were exclusively prescribed pregnancy category B and C medications.2 Azelaic acid 15% gel and clindamycin 1% gel, solution, or lotion were the most commonly prescribed treatments with 83.3% (55/66) and 69.7% (46/66) of patients trying to get pregnant and 75.7% (28/37) and 56.8% (21/37) of pregnant patients prescribed these medications, respectively. Only 13.5% (5/37) of currently pregnant patients were prescribed category C prescriptions, suggesting safe treatment of acne in pregnancy. In nonpregnancy-related encounters, prescription rates of azelaic acid (4.5%, 178/3,935) and clindamycin (54.0%, 2,124/3,935) were lower and recommendation rates of other pregnancy C medications including retinoids (59.8%, 2,355/3,935), spironolactone (10.2%, 401/3,935), and dapsone (9.1%, 358/3,935) were higher compared to pregnancy-related encounters. These findings suggest substantial adjustment of acne treatment regimens for safety in pregnancy and peri-pregnancy and recognition of the teratogenic effects of acne medications by providers. ABFM guidelines recommend avoidance of antibiotic monotherapy and encourage use of benzoyl peroxide as first-line treatment of acne in pregnancy to avoid antibiotic resistance.3,4 Of 37 pregnant patients, 6 (16.2%) were prescribed antibiotic monotherapy which was higher than the rate of 6.9% (270/3,935) in the nonpregnant population. Benzoyl peroxide 2.5–10% in the form of a face wash, cream, or gel was recommended at lower rates in the pregnant group (13.5%, 5/37) compared to those not pregnant (46.4%, 1,825/3,935). The higher rates of antibiotic monotherapy and lower rates of benzoyl peroxide prescribed in pregnant patients may reflect the limitations for ideal acne treatment and highlight a potential area for improvement. One limitation of this study is the relatively small sample size. Although prescription trends and generalizations can be inferred from the data, the sample size is not large enough to determine statistical significanc
{"title":"Analyzing trends in treatment of acne vulgaris in pregnancy: a retrospective study.","authors":"Swati P Garg,&nbsp;Saira Alvi,&nbsp;Roopal V Kundu","doi":"10.1097/JW9.0000000000000076","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000076","url":null,"abstract":"Acne vulgaris is an inflammatory disease of the skin common in pregnancy.1 Many first-line acne treatments are teratogenic, complicating management of this condition (Table 1).2 Although recommendations from the American Board of Family Medicine (ABFM) exist for treatment of acne in pregnancy,3 no studies have analyzed real-life data of acne management in pregnant patients. A retrospective study utilizing patient data from the Northwestern Medicine Enterprise Data Warehouse was approved by the Northwestern University Institutional Review Board (STU00037913). Data from over 40 clinic locations and 100 providers across the Chicago metropolitan area resulted in 4,050 analyzed patient encounters with a diagnosis of acne vulgaris. One hundred fifteen of these visits occurred in pregnancy-related encounters. Within our 115 patients, 57.4% (66) of patients were trying to get pregnant within the next year, 32.2% (37) were pregnant, and 10.4% (12) were breastfeeding (Table 2). Patients in this cohort were exclusively prescribed pregnancy category B and C medications.2 Azelaic acid 15% gel and clindamycin 1% gel, solution, or lotion were the most commonly prescribed treatments with 83.3% (55/66) and 69.7% (46/66) of patients trying to get pregnant and 75.7% (28/37) and 56.8% (21/37) of pregnant patients prescribed these medications, respectively. Only 13.5% (5/37) of currently pregnant patients were prescribed category C prescriptions, suggesting safe treatment of acne in pregnancy. In nonpregnancy-related encounters, prescription rates of azelaic acid (4.5%, 178/3,935) and clindamycin (54.0%, 2,124/3,935) were lower and recommendation rates of other pregnancy C medications including retinoids (59.8%, 2,355/3,935), spironolactone (10.2%, 401/3,935), and dapsone (9.1%, 358/3,935) were higher compared to pregnancy-related encounters. These findings suggest substantial adjustment of acne treatment regimens for safety in pregnancy and peri-pregnancy and recognition of the teratogenic effects of acne medications by providers. ABFM guidelines recommend avoidance of antibiotic monotherapy and encourage use of benzoyl peroxide as first-line treatment of acne in pregnancy to avoid antibiotic resistance.3,4 Of 37 pregnant patients, 6 (16.2%) were prescribed antibiotic monotherapy which was higher than the rate of 6.9% (270/3,935) in the nonpregnant population. Benzoyl peroxide 2.5–10% in the form of a face wash, cream, or gel was recommended at lower rates in the pregnant group (13.5%, 5/37) compared to those not pregnant (46.4%, 1,825/3,935). The higher rates of antibiotic monotherapy and lower rates of benzoyl peroxide prescribed in pregnant patients may reflect the limitations for ideal acne treatment and highlight a potential area for improvement. One limitation of this study is the relatively small sample size. Although prescription trends and generalizations can be inferred from the data, the sample size is not large enough to determine statistical significanc","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e076"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9a/1b/jw9-9-e076.PMC9997801.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9453743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Podiatric assessment in children and adults with epidermolysis bullosa: are foot and ankle patient-reported outcome measures (PROMs) able to measure the severity of podiatric involvement among EB patients? 大疱性表皮松解症儿童和成人的足部评估:足部和踝关节患者报告的结果测量(PROMs)是否能够测量EB患者足部病变的严重程度?
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000046
Joy Lynn Wong, Mohammed Tariq Khan, Timothy L Cowan, Dedée F Murrell

Epidermolysis bullosa (EB) represents a group of rare genetic skin fragility disorders characterized by (muco) cutaneous blistering upon minimal mechanical trauma. Ninety percent of EB patients experience podiatric symptoms which may affect physical functioning and emotional well-being. To date, an EB-specific podiatric assessment has not been outlined to guide clinicians in the assessment of EB podiatric involvement. This review describes the podiatric involvement of patients with EB and assesses the relevance of validated foot and ankle patient-reported outcome measures (PROMs) in measuring podiatric severity among EB patients. A literature review was conducted to identify systematic reviews and clinical studies investigating foot health and podiatric manifestations using validated foot health PROMs across foot and ankle conditions. Limited studies have documented the significance of podiatric involvement among EB patients. Existing EB-specific PROMs are not region-specific for assessing podiatric involvement. Among the foot and ankle PROMs, the Foot Health Status Questionnaire, Foot Function Index, and Manchester Oxford Foot Questionnaire were identified as potentially appropriate for assessing podiatric severity among EB patients, each with its strengths and limitations in assessment. However, they have not been widely validated for assessing dermatology-related diseases. An evaluation of the relevance of each identified PROM to EB podiatric assessment would enable future development of an appropriate EB-specific podiatric assessment tool that would guide management.

大疱性表皮松解症(EB)代表了一组罕见的遗传性皮肤脆弱性疾病,其特征是在最小的机械损伤下皮肤起疱。90%的EB患者会出现足部症状,这些症状可能会影响身体功能和情绪健康。到目前为止,还没有针对EB的足部评估概述来指导临床医生评估EB的足部病变。本综述描述了EB患者的足部疾病,并评估了经验证的足部和踝关节患者报告的结果测量(PROMs)在测量EB患者足部疾病严重程度中的相关性。我们进行了一项文献综述,以确定系统综述和临床研究,调查足部健康和足部症状,使用经过验证的足部健康PROMs进行足部和踝关节疾病。有限的研究证明了EB患者足部病变的重要性。现有的EB-specific PROMs并不是针对特定地区评估足部疾病的。在足部和踝关节PROMs中,足部健康状况问卷、足部功能指数和曼彻斯特牛津足部问卷被认为可能适用于评估EB患者的足部严重程度,各有其优点和局限性。然而,它们尚未被广泛验证用于评估皮肤相关疾病。对每个已确定的早PROM与EB足病评估的相关性进行评估,将有助于未来开发适当的EB特定足病评估工具,以指导管理。
{"title":"Podiatric assessment in children and adults with epidermolysis bullosa: are foot and ankle patient-reported outcome measures (PROMs) able to measure the severity of podiatric involvement among EB patients?","authors":"Joy Lynn Wong,&nbsp;Mohammed Tariq Khan,&nbsp;Timothy L Cowan,&nbsp;Dedée F Murrell","doi":"10.1097/JW9.0000000000000046","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000046","url":null,"abstract":"<p><p>Epidermolysis bullosa (EB) represents a group of rare genetic skin fragility disorders characterized by (muco) cutaneous blistering upon minimal mechanical trauma. Ninety percent of EB patients experience podiatric symptoms which may affect physical functioning and emotional well-being. To date, an EB-specific podiatric assessment has not been outlined to guide clinicians in the assessment of EB podiatric involvement. This review describes the podiatric involvement of patients with EB and assesses the relevance of validated foot and ankle patient-reported outcome measures (PROMs) in measuring podiatric severity among EB patients. A literature review was conducted to identify systematic reviews and clinical studies investigating foot health and podiatric manifestations using validated foot health PROMs across foot and ankle conditions. Limited studies have documented the significance of podiatric involvement among EB patients. Existing EB-specific PROMs are not region-specific for assessing podiatric involvement. Among the foot and ankle PROMs, the Foot Health Status Questionnaire, Foot Function Index, and Manchester Oxford Foot Questionnaire were identified as potentially appropriate for assessing podiatric severity among EB patients, each with its strengths and limitations in assessment. However, they have not been widely validated for assessing dermatology-related diseases. An evaluation of the relevance of each identified PROM to EB podiatric assessment would enable future development of an appropriate EB-specific podiatric assessment tool that would guide management.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e046"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9178572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer. 化疗的皮肤毒性:有色人种女性乳腺癌患者的教育干预。
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000073
Maham Ahmad, Sabrina Saeed, Brianna Olamiju, Andrea Silber, Jonathan Leventhal

Minority patients are more likely to require dose adjustments for chemotherapy, with cultural barriers and access to medical care cited as contributory factors.

Objective: We sought to pilot an educational intervention, in the form of a pamphlet, to evaluate the effectiveness of this tool in teaching skin of color (SoC) patients about potential dermatologic toxicities of chemotherapy that are relevant to their skin type.

Methods: At a chemotherapy infusion center, SoC patients (n = 26) who were receiving chemotherapy for breast cancer voluntarily consented to read an educational pamphlet and complete a series of survey questions before and after this educational intervention.

Results: Most participants identified as female (96%), African American/Black (81%), and non-Hispanic (85%); all respondents had obtained at least a high school degree. Survey responses revealed a significant increase in knowledge about the potential dermatologic effects of cancer treatment after this intervention. Notably, 100% of participants either agreed or strongly agreed that they would like to see other doctors use this educational tool as a form of patient education, that they would recommend this pamphlet to other patients who are starting cancer treatment, and that the pamphlet was easy to understand.

Limitations: Limitations of this study include small sample size and single-institution recruitment, which may limit generalizability. Furthermore, this study only included patients who are proficient in English.

Conclusion: This study pilots an effective educational tool that addresses dermatologic toxicities of chemotherapy that are relevant to SoC patients. Further multi-institutional studies with larger sample sizes and translation to other languages can overcome the limitations of this pilot study.

少数族裔患者更有可能需要调整化疗剂量,文化障碍和获得医疗护理的机会被认为是促成因素。目的:我们尝试以小册子的形式进行教育干预,以评估该工具在教导有色皮肤(SoC)患者与其皮肤类型相关的化疗潜在皮肤毒性方面的有效性。方法:在化疗输注中心,26例接受乳腺癌化疗的SoC患者自愿同意阅读教育小册子,并在教育干预前后完成一系列调查问题。结果:大多数参与者被确定为女性(96%),非洲裔美国人/黑人(81%)和非西班牙裔(85%);所有受访者都至少拥有高中学历。调查结果显示,在这种干预后,对癌症治疗潜在的皮肤病影响的认识显著增加。值得注意的是,100%的参与者同意或强烈同意他们希望看到其他医生使用这种教育工具作为患者教育的一种形式,他们会向其他开始癌症治疗的患者推荐这本小册子,而且小册子很容易理解。局限性:本研究的局限性包括样本量小和单一机构招募,这可能限制了通用性。此外,本研究仅包括精通英语的患者。结论:本研究为解决与SoC患者相关的化疗皮肤毒性提供了一种有效的教育工具。进一步的多机构研究,更大的样本量和翻译成其他语言可以克服这个试点研究的局限性。
{"title":"Dermatologic toxicities of chemotherapy: an educational intervention for skin of color women with breast cancer.","authors":"Maham Ahmad,&nbsp;Sabrina Saeed,&nbsp;Brianna Olamiju,&nbsp;Andrea Silber,&nbsp;Jonathan Leventhal","doi":"10.1097/JW9.0000000000000073","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000073","url":null,"abstract":"<p><p>Minority patients are more likely to require dose adjustments for chemotherapy, with cultural barriers and access to medical care cited as contributory factors.</p><p><strong>Objective: </strong>We sought to pilot an educational intervention, in the form of a pamphlet, to evaluate the effectiveness of this tool in teaching skin of color (SoC) patients about potential dermatologic toxicities of chemotherapy that are relevant to their skin type.</p><p><strong>Methods: </strong>At a chemotherapy infusion center, SoC patients (<i>n</i> = 26) who were receiving chemotherapy for breast cancer voluntarily consented to read an educational pamphlet and complete a series of survey questions before and after this educational intervention.</p><p><strong>Results: </strong>Most participants identified as female (96%), African American/Black (81%), and non-Hispanic (85%); all respondents had obtained at least a high school degree. Survey responses revealed a significant increase in knowledge about the potential dermatologic effects of cancer treatment after this intervention. Notably, 100% of participants either agreed or strongly agreed that they would like to see other doctors use this educational tool as a form of patient education, that they would recommend this pamphlet to other patients who are starting cancer treatment, and that the pamphlet was easy to understand.</p><p><strong>Limitations: </strong>Limitations of this study include small sample size and single-institution recruitment, which may limit generalizability. Furthermore, this study only included patients who are proficient in English.</p><p><strong>Conclusion: </strong>This study pilots an effective educational tool that addresses dermatologic toxicities of chemotherapy that are relevant to SoC patients. Further multi-institutional studies with larger sample sizes and translation to other languages can overcome the limitations of this pilot study.</p>","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e073"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9170951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deodorant/antiperspirant use and hair removal practices for hidradenitis suppurativa: recommendations from a single-center survey. 化脓性汗腺炎的除臭剂/止汗剂使用和脱毛实践:来自单中心调查的建议。
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000028
Brett Cutler, Erika Hagstrom, Teri M Greiling
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that frequently affects the axillae. Axillae are also tar-geted for societal hygiene practices: namely, the use of deodor- ants and antiperspirants and techniques for hair removal. HS is associated with an increased risk of hyperhidrosis and female hirsutism due to polycystic ovarian disease, further increasing the impact of these practices on quality of life. 1,2 Patients with HS are often unsure how to appropriately target physiologi- cal body odor and hair removal without worsening their HS. A 1982 case-control study concluded simply that deodorant, shaving, and chemical depilatories are not causative of HS, 3 but little guidance beyond this is available for patients or their providers.
{"title":"Deodorant/antiperspirant use and hair removal practices for hidradenitis suppurativa: recommendations from a single-center survey.","authors":"Brett Cutler,&nbsp;Erika Hagstrom,&nbsp;Teri M Greiling","doi":"10.1097/JW9.0000000000000028","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000028","url":null,"abstract":"Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder that frequently affects the axillae. Axillae are also tar-geted for societal hygiene practices: namely, the use of deodor- ants and antiperspirants and techniques for hair removal. HS is associated with an increased risk of hyperhidrosis and female hirsutism due to polycystic ovarian disease, further increasing the impact of these practices on quality of life. 1,2 Patients with HS are often unsure how to appropriately target physiologi- cal body odor and hair removal without worsening their HS. A 1982 case-control study concluded simply that deodorant, shaving, and chemical depilatories are not causative of HS, 3 but little guidance beyond this is available for patients or their providers.","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e028"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a9/09/jw9-9-e028.PMC9833445.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9178571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Association of lichen sclerosus and morphea with immune checkpoint therapy: a systematic review. 免疫检查点治疗与硬化地衣和morphea的关系:一项系统综述。
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000070
Leah Shin, Janellen Smith, Jessica Shiu, Christina N Kraus, Ashley N Elsensohn
The use of immune checkpoint inhibitors (ICIs) has been asso- ciated with various cutaneous immune-related adverse events (irAEs), including eczematous, psoriasiform, lichenoid, and bul- lous dermatoses. 1,2 Here, we evaluated reports of lichen sclerosus (LS) and morphea associated with ICIs. A literature search was conducted October 7, 2022 of PubMed, Cochrane, Embase, CINAHL, and Web of Science. Search terms: “lichen sclerosus,” “scleroderma, localized,” “mor-phea,” “immune checkpoint inhibitor,” “immunotherapy,” “ipili- mumab,” “nivolumab,” “pembrolizumab,” “atezolizumab,” avelumab,” “durvalumab,” “cemiplimab,” “dostarlimab,” and “relatlimab,” yielding 318 studies. Titles, abstracts, and full-text manuscripts were screened for relevance. Twenty-three studies were included
{"title":"Association of lichen sclerosus and morphea with immune checkpoint therapy: a systematic review.","authors":"Leah Shin,&nbsp;Janellen Smith,&nbsp;Jessica Shiu,&nbsp;Christina N Kraus,&nbsp;Ashley N Elsensohn","doi":"10.1097/JW9.0000000000000070","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000070","url":null,"abstract":"The use of immune checkpoint inhibitors (ICIs) has been asso- ciated with various cutaneous immune-related adverse events (irAEs), including eczematous, psoriasiform, lichenoid, and bul- lous dermatoses. 1,2 Here, we evaluated reports of lichen sclerosus (LS) and morphea associated with ICIs. A literature search was conducted October 7, 2022 of PubMed, Cochrane, Embase, CINAHL, and Web of Science. Search terms: “lichen sclerosus,” “scleroderma, localized,” “mor-phea,” “immune checkpoint inhibitor,” “immunotherapy,” “ipili- mumab,” “nivolumab,” “pembrolizumab,” “atezolizumab,” avelumab,” “durvalumab,” “cemiplimab,” “dostarlimab,” and “relatlimab,” yielding 318 studies. Titles, abstracts, and full-text manuscripts were screened for relevance. Twenty-three studies were included","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e070"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/e4/jw9-9-e070.PMC9851696.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9191205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemia. 慢性淋巴细胞白血病一例罕见的病毒相关棘毛发育不良。
Q2 Medicine Pub Date : 2023-03-01 DOI: 10.1097/JW9.0000000000000069
Rachel Choi, Shaman Bhullar, Jennifer McNiff, Justin Persico, Jonathan Leventhal
Viral-associated trichodysplasia spinulosa (VATS) is a cuta- neous eruption of folliculo-centric shiny papules and alo-pecia that most commonly occurs in transplant recipient patients. 1 Here, we present an extremely rare case of VATS in a female patient with chronic lymphocytic leukemia (CLL). An informed consent was obtained from the patient for this report.A 63-year-old female presented with a 2-month history of multiple reddish-pinkish papules on her face in the setting of long-standing CLL. Physical examination also showed leonine facies, superciliary madarosis
{"title":"A rare case of viral-associated trichodysplasia spinulosa in a patient with chronic lymphocytic leukemia.","authors":"Rachel Choi,&nbsp;Shaman Bhullar,&nbsp;Jennifer McNiff,&nbsp;Justin Persico,&nbsp;Jonathan Leventhal","doi":"10.1097/JW9.0000000000000069","DOIUrl":"https://doi.org/10.1097/JW9.0000000000000069","url":null,"abstract":"Viral-associated trichodysplasia spinulosa (VATS) is a cuta- neous eruption of folliculo-centric shiny papules and alo-pecia that most commonly occurs in transplant recipient patients. 1 Here, we present an extremely rare case of VATS in a female patient with chronic lymphocytic leukemia (CLL). An informed consent was obtained from the patient for this report.A 63-year-old female presented with a 2-month history of multiple reddish-pinkish papules on her face in the setting of long-standing CLL. Physical examination also showed leonine facies, superciliary madarosis","PeriodicalId":53478,"journal":{"name":"International Journal of Women''s Dermatology","volume":"9 1","pages":"e069"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9170983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Women''s Dermatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1